0HC7 Stock Chart & Stats
$127.79
-$2.68(-2.33%)
At close: 4:00 PM EDT
$127.79
-$2.68(-2.33%)
Day’s Range― - ―
52-Week Range$79.51 - $221.10
Previous CloseN/A
Volume2.40K
Average Volume (3M)3.29K
Market Cap
$12.95B
Enterprise Value$21.25K
Total Cash (Recent Filing)$1.63B
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)223.7
Beta1.60
Next Earnings
Nov 04, 2026EPS Estimate
2.56Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.48
Shares Outstanding118,005,060
10 Day Avg. Volume4,439
30 Day Avg. Volume3,286
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.75
Price to Sales (P/S)3.24
P/FCF Ratio24.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$175.31Price Target Upside37.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)11.48
Revenue Forecast (FY)$6.12B
Bulls Say, Bears Say
Bulls Say
Cash GenerationThe sharp recovery in operating and free cash flow strengthens liquidity and gives Albemarle more capacity to fund operations, reduce debt, and pursue selected growth investments. Improved cash conversion also provides resilience through the lithium cycle, although sustainability remains tied to market conditions.
Balance SheetSubstantial debt reduction and low debt relative to equity improve financial flexibility during a cyclical recovery. A stronger balance sheet can support continued investment in lithium capacity and technology while reducing the pressure that leverage would otherwise place on cash allocation.
Lithium TechnologyThe DLE results indicate a potentially meaningful process advantage in lithium recovery and water efficiency compared with conventional ponds. If commercialized successfully, the technology could improve resource utilization, support future capacity growth, and strengthen Albemarle's position in strategic lithium supply.
Bears Say
Cyclical EarningsThe rebound in profitability remains incomplete, with earnings still well below prior-cycle performance and a history of significant losses. This volatility indicates that Albemarle's returns remain highly exposed to lithium pricing and demand cycles, limiting confidence in near-term earnings durability.
CGP3 Volume DelayThe delayed CGP3 ramp removes expected production from the near-term outlook and lowers 2026 energy-storage volumes. Until the facility returns to full operation, Albemarle has less capacity to convert market demand into sales, while execution and restart risks can weigh on segment recovery.
Margin ExposureSpodumene pricing and inventory timing create a persistent mismatch between input costs and realized lithium prices. That exposure can compress margins even when demand is healthy, making profitability less predictable and increasing sensitivity to changes in market pricing and contract timing.
Albemarle News
0HC7 FAQ
What was Albemarle’s price range in the past 12 months?
Albemarle lowest share price was $79.51 and its highest was $221.10 in the past 12 months.
What is Albemarle’s market cap?
Albemarle’s market cap is $12.95B.
When is Albemarle’s upcoming earnings report date?
Albemarle’s upcoming earnings report date is Nov 04, 2026 which is in 36 days.
How were Albemarle’s earnings last quarter?
Albemarle released its earnings results on Aug 05, 2026. The company reported $3.75 earnings per share for the quarter, beating the consensus estimate of $3.203 by $0.547.
Is Albemarle overvalued?
According to Wall Street analysts Albemarle’s price is currently Undervalued.
Does Albemarle pay dividends?
Albemarle pays a Quarterly dividend of $0.41 which represents an annual dividend yield of 1.51%. See more information on Albemarle dividends here
What is Albemarle’s EPS estimate?
Albemarle’s EPS estimate is 2.56.
How many shares outstanding does Albemarle have?
Albemarle has 118,005,060 shares outstanding.
What happened to Albemarle’s price movement after its last earnings report?
Albemarle reported an EPS of $3.75 in its last earnings report, beating expectations of $3.203. Following the earnings report the stock price went up 6.077%.
Which hedge fund is a major shareholder of Albemarle?
Currently, no hedge funds are holding shares in GB:0HC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Albemarle Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$175.31 (37.18% Upside)
$175.31 (37.18% Upside)
Blogger Sentiment
Bullish
GB:0HC7 Sentiment 70%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.29%
12-Months-Change
Fundamentals
Return on Equity
1.51%
Trailing 12-Months
Asset Growth
-8.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Albemarle
Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts. The Lithium division supplies a variety of lithium compounds, including lithium carbonate, hydroxide, and chloride, alongside critical reagents like butyllithium. These materials are vital for manufacturing lithium-ion batteries found in electric vehicles and consumer electronics, as well as for high-performance greases, thermoplastic elastomers used in tires and plastics, and as catalysts for chemical reactions, organic synthesis in areas like steroid chemistry, vitamins, and the pharmaceutical industry. This segment also delivers cesium products for chemical and pharmaceutical applications, zirconium, barium, and titanium for pyrotechnic devices such as airbag initiators, offers expert technical services for the safe handling of reactive lithium products, and provides recycling solutions for lithium-containing by-products. The Bromine segment focuses on bromine and bromine-based fire safety compounds. It produces an array of specialty chemicals, including elemental bromine, various bromides, and brominated powdered activated carbon, which are utilized in chemical synthesis, fluids for oil and gas drilling, mercury emission control, water purification, and food processing. Additionally, it provides tertiary amines, which serve as key ingredients in surfactants, biocides, and sanitizers. Finally, the Catalysts segment offers a range of catalytic agents, including those for hydroprocessing, isomerization, and alkylation, alongside fluidized catalytic cracking (FCC) catalysts and additives, as well as organometallics and curatives. Albemarle's products are integral to numerous industries, including energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection. Established in 1887, the company's headquarters are located in Charlotte, North Carolina.
0HC7 Company Deck
0HC7 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strong operational and financial quarter highlighted by robust top‑line growth (net sales +31%), outsized EBITDA expansion (+155%), exceptional cash generation (Q2 cash from operations $710M and $638M FCF) and meaningful cost/productivity gains. Management raised Specialties outlook, advanced DLE pilot results (>90% recoveries) and signaled disciplined capital allocation with attractive brownfield growth options. Offsetting risks include a June fire at Greenbushes (CGP3) that delayed some volume, tight industry inventories and spodumene supply constraints, supply chain impacts from Middle East disruptions (estimated $70–$90M effect), and near‑term margin sensitivity from spodumene price timing. Overall, the positive operational execution, strong cash flow and upgraded outlooks outweigh the near‑term operational and market headwinds.View all GB:0HC7 earnings summaries0HC7 Net sales Breakdown
52.70% Energy Storage
26.57% Specialties
20.73% Ketjen
0HC7 Stock 12 Month Forecast
Average Price Target
$175.31
▲(37.18% Upside)
Technical Analysis
Ashland
―
Eastman Chemical
―
Sociedad Quimica Y Minera SA
―
Element Solutions
―
Chemours Company
―